NCT01503021View on ClinicalTrials.gov

Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

718

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
End Stage Renal DiseaseChronic Kidney Disease
Interventions
DRUG

SFP

Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate

OTHER

Placebo

Dialysis with standard liquid bicarbonate concentrate without iron

Trial Locations (31)

20748

Camp Springs

27804

Rocky Mount

29209

Columbia

30060

Marietta

33319

Lauderhill

36688

Mobile

38801

Tupelo

39501

Gulfport

39648

McComb

45428

Dayton

47201

Columbus

60616

Chicago

61603

Peoria

63376

City of Saint Peters

67214

Wichita

68510

Lincoln

70808

Baton Rouge

71101

Shreveport

75061

Irving

75234

Research Across America, Houston

75701

Tyler

76508

Temple

77051

Houston

78572

Mission

80002

Arvada

80031

Westminster

89511

Reno

91324

Northridge

L1E 3C3

Courtice

H3A 1A1

Montreal

54P 0W5

Regina

All Listed Sponsors
lead

Rockwell Medical Technologies, Inc.

INDUSTRY

NCT01503021 - Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis | Biotech Hunter | Biotech Hunter